• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺小活检组织和细胞学细胞块中CD8评分的定量图像分析。

Quantitative image analysis for CD8 score in lung small biopsies and cytology cell-blocks.

作者信息

Monaco Sara E, Dacic Sanja, Seigh Lindsey, Hartman Douglas J, Xing Juan, Pantanowitz Liron

机构信息

Department of Pathology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.

出版信息

Cytopathology. 2020 Sep;31(5):393-401. doi: 10.1111/cyt.12812. Epub 2020 Apr 6.

DOI:10.1111/cyt.12812
PMID:32065467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7429339/
Abstract

INTRODUCTION

Immunotherapy has shown promising results in non-small cell lung cancer (NSCLC), for which tumour-infiltrating cytotoxic (CD8+) T cells play a critical role. We investigated the utility of image analysis (IA) to quantify CD8+ T cells in a series of matched small biopsies and resections of NSCLC.

METHODS

CD8 immunohistochemistry was performed on cell-blocks (CB), core needle biopsies (CNB) and corresponding resections from primary NSCLCs. Slides were digitised using an Aperio AT2 scanner (Leica) and annotated by whole slide image (WSI) or fields of view occupied by tissue spots (TS). Quantitative IA was performed with a customised Aperio algorithm (Leica). CD8 scores (number of T cells with 1-3+ staining/total area) were then compared.

RESULTS

Forty-four cases with CB or CNB material and a corresponding resection were analysed. Average CD8 score was determined in CB (7.67 WSI, 77.67 TS) and/or CNB (47.35 WSI, 325.67 TS), and corresponding resections (190.35 WSI, 336.58 TS). CD8 score concordance was highest (78.6%) for CNBs using WSI annotation. Overall, small biopsies (CB or CNB) correlated with the resection in 71.4% cases using WSI and 63.3% cases using TS annotation. IA performed better for low CD8 scores.

CONCLUSIONS

These findings show that CD8 density in NSCLC can be quantified by IA in small biopsies and cell blocks, achieving the best concordance using WSI scores. Discrepancies were attributed to values near the cut-off and background detection of staining. These data warrant future studies with more cases and follow-up data to further investigate the clinical utility of IA for CD8 analysis in NSCLC.

摘要

引言

免疫疗法在非小细胞肺癌(NSCLC)中已显示出有前景的结果,其中肿瘤浸润性细胞毒性(CD8 +)T细胞起着关键作用。我们研究了图像分析(IA)在一系列匹配的NSCLC小活检组织和手术切除组织中定量CD8 + T细胞的实用性。

方法

对原发性NSCLC的细胞块(CB)、粗针活检(CNB)及相应手术切除组织进行CD8免疫组织化学检测。使用Aperio AT2扫描仪(徕卡)对玻片进行数字化处理,并通过全玻片图像(WSI)或组织斑点(TS)占据的视野进行标注。使用定制的Aperio算法(徕卡)进行定量IA。然后比较CD8评分(1 - 3 +染色的T细胞数量/总面积)。

结果

分析了44例有CB或CNB材料及相应手术切除组织的病例。在CB(7.67 WSI,77.67 TS)和/或CNB(47.35 WSI,325.67 TS)以及相应手术切除组织(190.35 WSI,336.58 TS)中确定了平均CD8评分。使用WSI标注时,CNB的CD8评分一致性最高(78.6%)。总体而言,使用WSI标注时,71.4%的病例中小活检组织(CB或CNB)与手术切除组织相关,使用TS标注时为63.3%。IA对低CD8评分的表现更好。

结论

这些发现表明,NSCLC中的CD8密度可通过IA在小活检组织和细胞块中进行定量,使用WSI评分时一致性最佳。差异归因于接近临界值的值和染色的背景检测。这些数据值得未来进行更多病例和随访数据的研究,以进一步探讨IA在NSCLC中进行CD8分析的临床实用性。

相似文献

1
Quantitative image analysis for CD8 score in lung small biopsies and cytology cell-blocks.肺小活检组织和细胞学细胞块中CD8评分的定量图像分析。
Cytopathology. 2020 Sep;31(5):393-401. doi: 10.1111/cyt.12812. Epub 2020 Apr 6.
2
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.非吸烟肺腺癌患者肿瘤微环境不良预后免疫特征的测定
Eur J Cancer. 2017 Nov;86:15-27. doi: 10.1016/j.ejca.2017.08.026. Epub 2017 Sep 23.
3
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.程序性死亡配体 1 检测在非小细胞肺癌细胞学细胞块和抽吸涂片制备中的应用。
Cancer Cytopathol. 2018 May;126(5):342-352. doi: 10.1002/cncy.21987. Epub 2018 Mar 2.
4
An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study.一种用于经皮穿刺活检全切片图像中前列腺癌诊断的人工智能算法:一项盲法临床验证与应用研究。
Lancet Digit Health. 2020 Aug;2(8):e407-e416. doi: 10.1016/S2589-7500(20)30159-X.
5
Heterogeneity of CD8 tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.非小细胞肺癌中CD8肿瘤浸润淋巴细胞的异质性:对患者预后评估的影响及不同采样策略定量比较
Cancer Immunol Immunother. 2017 Jan;66(1):33-43. doi: 10.1007/s00262-016-1908-4. Epub 2016 Oct 21.
6
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.非小细胞肺癌活检的自动图像分析预测抗 PD-L1 治疗反应。
J Immunother Cancer. 2019 May 6;7(1):121. doi: 10.1186/s40425-019-0589-x.
7
Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.激素受体和 HER2 在乳腺癌骨转移中的评估:细针抽吸细胞块与脱钙芯针活检的比较。
Cancer Cytopathol. 2020 Feb;128(2):133-145. doi: 10.1002/cncy.22226. Epub 2019 Dec 28.
8
Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas.非小细胞肺癌中树突状细胞密度、HMGB1表达与肿瘤浸润淋巴细胞的关系
Appl Immunohistochem Mol Morphol. 2014;22(2):105-13. doi: 10.1097/PAI.0b013e3182849808.
9
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.细胞学细胞块适合用于肺癌中 PD-L1 的免疫组织化学检测。
Ann Oncol. 2018 Jun 1;29(6):1417-1422. doi: 10.1093/annonc/mdy126.
10
CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.CD8+ T 细胞浸润在乳腺癌和结肠癌中的研究:组织学和统计学分析。
PLoS One. 2018 Jan 10;13(1):e0190158. doi: 10.1371/journal.pone.0190158. eCollection 2018.

本文引用的文献

1
Grading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material.基于细针抽吸细胞块材料的 Ki-67 指数评估对胰腺神经内分泌肿瘤进行分级。
Am J Clin Pathol. 2020 Jan 1;153(1):74-81. doi: 10.1093/ajcp/aqz110.
2
PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.非小细胞肺癌患者的组织学标本和配对胸腔积液细胞块中的 PD-L1 检测。
Respirology. 2019 Dec;24(12):1198-1203. doi: 10.1111/resp.13614. Epub 2019 Jun 17.
3
Grading pancreatic neuroendocrine neoplasms by Ki-67 staining on cytology cell blocks: manual count and digital image analysis of 58 cases.通过细胞学细胞块上的Ki-67染色对胰腺神经内分泌肿瘤进行分级:58例的手工计数和数字图像分析
J Am Soc Cytopathol. 2016 Sep-Oct;5(5):286-295. doi: 10.1016/j.jasc.2016.03.002. Epub 2016 Mar 30.
4
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials.黑色素瘤的联合靶向治疗与免疫治疗:对肿瘤微环境及早期临床试验结果影响的综述
Ther Adv Med Oncol. 2019 Feb 19;11:1758835919830826. doi: 10.1177/1758835919830826. eCollection 2019.
5
The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.免疫评分是 II 期和 III 期结直肠癌的一种优越的预后工具,并且与肿瘤浸润单核细胞中的程序性死亡配体 1(PD-L1)表达显著相关。
Ann Surg Oncol. 2019 Feb;26(2):415-424. doi: 10.1245/s10434-018-07110-z. Epub 2018 Dec 19.
6
Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.自动化定量图像分析 CD8 评分在头颈部鳞状细胞癌中的应用。
Oral Oncol. 2018 Nov;86:278-287. doi: 10.1016/j.oraloncology.2018.10.005. Epub 2018 Oct 11.
7
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
8
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.阿替利珠单抗治疗转移性三阴性乳腺癌患者的长期临床结局和生物标志物分析:一项 I 期研究。
JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.
9
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.共识免疫评分用于结肠癌分类的国际验证:预后和准确性研究。
Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.
10
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.用于阿替利珠单抗的程序性死亡受体配体1(PD-L1)补充诊断免疫组织化学检测法(SP142)的研发
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594.